Not provided
Not provided
Not provided
Not provided
Medical practices have evolved and are not conform with the study procedure. Actually, all patients receive an ambulatory ECG telemetry monitoring
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to show that an ambulatory ECG telemetry monitoring of some patients hospitalized for cerebral infarction increases the frequency of the diagnosis of atrial fibrillation, cause of their stroke, and reinforces the protection against recurrences.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| holter-ECG | Experimental | Implementation of an ECG Holter during hospitalisation patient. |
|
| Crontrole | No Intervention | No implementation of an ECG Holter |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ECG telemetry | Device | ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic impact of outpatient ECG telemetry | Percentage of patients hospitalized for cerebral infarction and with a diagnosis of atrial fibrillation allowed by the use of ambulatory ECG telemetry. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Identification of prognostic factors to identify de novo atrial fibrillation | Retrospective evaluation of prognostic criteria (clinical data, biomarkers, abdominal MRI) in patients with a diagnosis of AF | 6 months |
| Evaluate the therapeutic impact (prescription anticoagulant) at the end of hospitalisation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bertrand Lapergue, MD | Hopital Foch | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital Foch | Suresnes | 92150 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002544 | Cerebral Infarction |
| D020521 | Stroke |
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D020520 | Brain Infarction |
| D002545 | Brain Ischemia |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Percentage of patients on anticoagulation at the end of hospitalisation |
| 6 months |
| Evaluate the benefit on the recurrence rate of cerebral infarction after the exit of the service | Percentage of IC recurrence in the department and within 3 months of the IC diagnosis | 3 months |
| D002493 |
| Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D007238 | Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009336 | Necrosis |
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |